This program is intended for healthcare professionals only.

Primary biliary cholangitis
Login
Register

This program is intended for healthcare professionals only.

Popular searches
Popular searches

ELATIVE updates from EASL 2024

  • PBC, Video

Professor Marco Carbone reviews the latest updates from the ELATIVE trial of elafibranor, presented at EASL 2024 in Milan, Italy. Discover key insights on efficacy, quality of life improvements, and the broader significance of these results.

This video offers subtitles in English, French, German, and Italian, which can be enabled using the subtitle icon  in the video player.

Enjoyed this? You might like:

  • News article
  • AASLD 2023

Adding bezafibrate to OCA shows treatment promise for PBC

Combining obeticholic acid with bezafibrate 400 mg/day shows therapeutic potential in patients with primary biliary cholangitis in two phase 2 trials.
Find out more
  • News article
  • AASLD 2023

Denosumab performs well against bisphosphonate for PBC-related osteoporosis

Denosumab is comparable to bisphosphonates for treating osteoporosis in patients with primary biliary cholangitis, but with fewer adverse effects.
Find out more
  • News article
  • AASLD 2023

Positive RESPONSE for seladelpar in patients with PBC

RESPONSE trial findings show seladelpar improves markers of disease activity and reduces pruritus in patients with primary biliary cholangitis.
Find out more
  • News article
  • AASLD 2023

ELATIVE: Elafibranor shows treatment efficacy in patients with PBC

ELATIVE trial shows that elafibranor significantly improves biochemical response in patients with primary biliary cholangitis with anti-pruritic benefits.
Find out more
  • News article
  • AASLD 2023

Complete biochemical and POISE response seen with second-line OCA in real-world setting

Obeticholic acid positively affects liver function among patients with primary biliary cholangitis in the second-line treatment setting.
Find out more
  • Video
  • AASLD 2023

Gideon Hirschfield highlights noteworthy findings on PBC

Dr Gideon Hirschfield discusses some of the highlights on primary biliary cholangitis from The Liver Meeting 2023, with a focus on the RESPONSE trial of seladelpar.
Watch now
  • Video
  • AASLD 2023

Kris Kowdley’s analysis of breakthrough research on PBC

Dr Kris Kowdley comments on some of the key data in primary biliary cholangitis, presented at The Liver Meeting 2023, including the ELATIVE trial involving elafibranor.
Watch now
  • Video
  • AASLD 2023

Andreas Kremer discusses advances in second-line obeticholic acid

Prof. Andreas Kremer provides his insights on studies on second-line obeticholic acid presented at The Liver Meeting 2023: its use in a real-world setting and as combination therapy with bezafibrate.
Watch now

Like this content?

Share with a colleague

Funding

This program is made possible thanks to an independent educational grant from Ipsen.

X-twitter Linkedin Facebook Youtube
Contact us

Email: [email protected]

Springer Healthcare IME, The Campus, 4 Crinan Street, London N1 9XW
Terms & conditions
Privacy policy
© 2025 Springer Healthcare LLC.
Springer Health+ IME is part of Springer Nature. All rights reserved.